Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

AI Summary

Ascletis initiated a global Phase III clinical trial for its oral small molecule GLP-1 drug ASC30 targeting obesity and overweight patients, with approximately 4,600 participants across the U.S., Europe, and Canada. The company also announced positive preclinical data on a novel oral small molecule fixed-dose combination targeting GLP-1/GIP/Amylin.

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in non-human primates announced for first-in-class once-daily oral small molecule GLP-1/GIP/amylin fixed-dose combination. -Industry leading one-pill once-daily oral small molecule portfolio […]